# SOM Innovation Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/som-innovation-biotech

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.sombiotech.com
- Total disclosed funding: $17M
- Latest round: Series B (Dec 3, 2023)
- Investors on record: 3

## About

Founded in 2009 by Raúl Insa (President/CEO), and based in Barcelona, Spain, SOM Innovation Biotech, SA is a biotechnology company that develops and repurposes drugs for addressing diseases of the central nervous system. In December 2023, the firm raised USD 17 million in series B funding from EIB and the Prevail Partner Fund. SOM Innovation Biotech, SA’s partners include Clinic Barcelona, Duchenne Parent Project, Corino Therapeutics, U-Cell Therapeutics, etc.

The company uses artificial intelligence to discover new indications for existing drugs, reducing the risk of clinical development for diseases like TTR Amyloidosis, Huntington's disease, Tardive dyskinesia, Adrenoleukodystrophy, Adrenomyeloneuropathy, Phenylketonuria, and Niemann-Pick disease. To help reduce drug development costs and development time, the company offers drug repurposing activities that focus on diseases with little or no available medication.

SOM Innovation Biotech, SA plans to use the December 2023 funding to further enhance its product offering.

## Funding rounds

- Series B, Dec 3, 2023, $17M — European Investment Bank, Prevail Partners
- Series A, Jan 1, 2011 — Innova31

## Investors

- Innova31 (https://capitalatlas.ai/funds/innova31) — Series A
- European Investment Bank (https://capitalatlas.ai/funds/european-investment-bank) — Series B
- Prevail Partners (https://capitalatlas.ai/funds/prevail-partners) — Series B